Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2371 to 2385 of 7686 results

  1. Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217

    Awaiting development [GID-TA11192] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer ID6481

    Awaiting development [GID-TA11607] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Seladelpar for previously treated primary biliary cholangitis ID6429

    In development [GID-TA11540] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407

    In development [GID-TA11498] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  6. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development [GID-TA11470] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    Awaiting development [GID-TA11440] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476

    Awaiting development [GID-TA11584] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

    In development [GID-TA11316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Intrapartum Care - maternal hyponatremia

    In development [GID-NG10431] Expected publication date: TBC

    NICE guideline
    In development

  12. Nemolizumab for treating prurigo nodularis [ID6451]

    In development [GID-TA11566] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  13. Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

    In development [GID-TA11503] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development